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Summary Background Foretinib is a small-molecule, oral
multikinase inhibitor primarily targeting the mesenchymal
epithelial transition (MET) factor receptor, and the vascular
endothelial growth factor receptor 2. We conducted a phase II
study to evaluate the single-agent activity and tolerability of
foretinib in patients with recurrent/metastatic squamous cell
carcinoma of the head and neck (SCCHN).MethodsAn open-
label, single-arm, multicenter trial employing a Simon 2-stage
design was conducted with a total of 41 patients planned for
the study. One or more responses in the first 14 patients were
required in order to progress to the second stage. Foretinib was
administered as 240 mg orally for 5 consecutive days of
a 14-day treatment cycle (5/9 schedule) to patients with recur-
rent and/or metastatic SCCHN. Results Fourteen patients were
enrolled. The study did not meet criteria for continuing to the
second stage. A maximum of 30 cycles were administered
(median04.0). Fifty percent of patients (7/14) showed stable
disease (SD), 43 % of patients (6/14) experienced tumor
shrinkage and two patients had prolonged disease stabilization
for ≥13 months. The most common adverse events were
fatigue, constipation and hypertension, which were manage-
able with additional medication or adjustments to the dosing
schedule. Conclusion Foretinib 240 mg on a 5/9 schedule was
generally well tolerated. SD was the best-observed outcome,
with minor tumor shrinkage detected in nearly half of all
patients. The efficacy results, prolonged disease stabilization
and tolerable side-effect profile, support further investigation,
possibly in combination with other targeted agents or cyto-
toxic chemotherapy for SCCHN.
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Introduction
Head and neck cancer (HNC) represents a heterogeneous
group of potentially deadly cancers. Approximately 650,000
HNC diagnoses are made each year worldwide with almost
50,000 cases and 11,000 deaths occurring in the United
States alone [1, 2]. Overall 5-year survival rates for patients
with HNC are below 50 % [3]. Although the head and neck
comprise a variety of tissue types, squamous cell carcino-
mas originating from mucosal surfaces represent >90 % of
all cases of HNC [3]. The risk factors for squamous cell
carcinomas of the head and neck (SCCHN) have been
strongly linked with tobacco and alcohol use as well as with
human papillomavirus [3].
Treatment modalities for SCCHN include surgery, radia-
tion therapy, and chemotherapy [4]. Most patients with
SCCHN present with advanced locoregional disease [5].
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With advanced SCCHN, only 35 % to 55 % of patients
survive and remain disease-free for 3 years, despite aggres-
sive therapy [1]. Locoregional recurrence develops in 30 %
to 40 % of patients and distant metastases develop in 12 %
to 22 % of patients [6]. Once the disease is recurrent/meta-
static, combination chemotherapy using a platinum-based
regimen remains the standard of care for SCCHN. The
addition of cetuximab, an epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor, to chemotherapeutic agents
has provided a modest survival benefit (10 vs. 7 months) [7].
Nevertheless, palliative treatment of recurrent/metastatic
SCCHN remains largely ineffective and little progress has
been made. More effective, targeted treatments are needed.
The mesenchymal epithelial transition (MET) factor recep-
tor and its sole ligand, hepatocyte growth factor (HGF), are
strongly overexpressed in >80% of SCCHN [8, 9]. Activation
of the MET factor receptor by HGF stimulates cell prolifera-
tion, survival and motility, thus promoting cancer cell metas-
tases [9, 10]. There is evidence to suggest that the HGF/MET
signaling pathway may represent a promising target in the
treatment of recurrent SCCHN, as preclinical data have pro-
vided additional support for activity with MET inhibitors in
SCCHN models [8, 9, 11]. Vascular endothelial growth factor
(VEGF) is also upregulated in patients with SCCHN [12].
VEGF upregulation in SCCHN has been linked to tumor
angiogenesis and disease severity [13, 14]. However, targeting
VEGF receptors alone in recurrent or metastatic cancers of the
head and neck has shown modest objective response rates;
data from one study showed only one minor response and one
partial response out of 31 evaluable patients [15]. HGF and
VEGF may, therefore, act in concert to spur angiogenesis and
metastasis in patients with SCCHN. Thus, targeting both the
HGF/MET and VEFG signaling pathways is an attractive
therapeutic approach [16]. Previous studies combining anti-
angiogenic agents with other approaches have shown prom-
ise with combination approaches using anti-angiogenic
agents, such as the combination of erlotinib, an EGFR
tyrosine kinase inhibitor, and bevacizumab [17]. Other
targeted therapies used as single agents have shown limited
or no activity for SCCHN [18].
Foretinib (also known as GSK1363089 or XL880) is an oral
multikinase inhibitor that primarily targets signaling of HGF/
MET (in vitro IC50 of 3 nmol/L) and the VEGF receptor-2
(VEGFR2) (in vitro IC50 of 7 nmol/L) [19] signaling pathways
by binding in the adenosine triphosphate pocket of both MET
and VEGFR2. In preclinical studies, foretinib induced tumor
hemorrhage and necrosis in human xenografts [20]. Foretinib
also targets several other receptor tyrosine kinases (RTKs),
including the MET-related recepteur d'origine nantais (RON)
receptor (in vitro IC50 of 3 nmol/L) [19] and additional RTKs
involved in tumor angiogenesis (AXL and TIE-2) [20, 21].
While the role of RON in SCCHN remains unclear, its effects
appear to largely overlap with MET, and in other tumor types
synergy has been reported with the inhibition of both targets
[22]. MET has been evaluated extensively as a potential treat-
ment target for SCCHN, with promising results [8, 9], and
foretinib demonstrated activity against human SCCHN cell
lines [23]. Foretinib has also shown antitumor activity in clin-
ical studies of papillary renal cell carcinoma and hepatocellular
carcinoma [24, 25], and may have the potential to prevent
tumor growth in SCCHN, chiefly by reducing tumor cell pro-
liferation and metastasis through HGF/MET inhibition and
decreasing angiogenesis through VEGFR2 pathway inhibition.
The primary purpose of this study was to evaluate the
response rate for single-agent foretinib treatment in patients
with recurrent and/or metastatic SCCHN, and to assess
foretinib safety and tolerability in SCCHN patients. This is
the first report evaluating a MET inhibitor in SCCHN.
Patients and methods
Eligible patients were ≥18 years of age with histologically
or cytologically confirmed recurrent and/or metastatic
SCCHN who were not eligible for curative-intent surgery
or radiotherapy. Patients had measurable disease according
to Response Evaluation Criteria In Solid Tumors (RECIST)
1.0, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of ≤1 [26]. All patients participating in the
study provided informed consent.
Exclusion criteria included previous radiation therapy
(>25 % of bone marrow) within 30 days of study treatment,
>1 regimen of systemic anticancer therapy for disease that
had recurred or was metastatic, except for adjuvant or neo-
adjuvant chemotherapy, those who had disease progression
within 6 months after completion of curative-intent therapy,
and patients at high risk of bleeding.
Study design
This was a single-arm, phase II, multicenter (all in the
United States), non-randomized, open-label, Simon 2-stage
safety and efficacy study [27]. The primary objectives of
this study were to determine the response rate according to
RECIST 1.0 [28] for foretinib treatment in patients with
SCCHN, and to evaluate the safety and tolerability of fore-
tinib. Secondary objectives included an assessment of
progression-free survival (PFS), duration of response, over-
all survival (OS) and the pharmacokinetic parameters of
foretinib. Foretinib was administered at doses of 240 mg
orally for 5 consecutive days of a 14-day treatment cycle (5/
9 schedule). Patients fasted from 2 h prior to 1 h after each
dose. In the absence of progressive disease and unacceptable
toxicity, patients were eligible to continue with foretinib
treatment for 1 year or longer. If the patient required addi-
tional anticancer therapy (e.g. chemotherapy, radiation or
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surgery), foretinib dosing was discontinued. The relation-
ship between foretinib trough concentrations and percent
change from baseline in tumor size was examined.
Assessments
Tumor assessments were performed within 14 days before
dosing. During the study treatment period tumor response
was assessed after 8 weeks. Patients were asked to return to
the study site 30 days after the last dose of foretinib for
laboratory assessments and clinical examination. Patients were
contacted for follow-up at 90 and 180 days after the last dose.
Toxicity grade of adverse events (AEs), serious AEs and lab-
oratory variables were defined by the National Cancer Institute
Common Terminology Criteria for Adverse Events v3.0.
Statistical analyses
A total of 14 patients were enrolled into stage 1 (to ensure a total
of 12 evaluable patients). If no patients had either a complete
response (CR) or partial response (PR) to treatment in stage 1,
then the study was to be halted. If one or more patients had a
response in stage 1, a second stage was to be opened to enroll
additional patients up to a total of 41 patients (to ensure a total of
35 evaluable patients). EGFR inhibitors have a response rate of
5 % to 13 % as single agents, and a similar response rate was
hypothesized to be meaningful in the current study [7, 29]. The
study had a type 1 error rate of 5 % for the null hypothesis that
the response rate is at least 10 %, with 80 % power for an
alternative response rate of at least 25 %.
Response rates were summarized with exact 95 % confi-
dence intervals using Klopper–Pearson methods, and PFS, sta-
ble disease (SD) and OS data were summarized using Kaplan–
Meier methods with 95 % confidence intervals for medians.
Foretinib exposure measures for all analyses were the average
trough concentration for foretinib across days 5, 19, 33 and 47,
which represented the trough concentration after 4 days of
dosing. Ordinal logistic regression was used to examine the
maximal grade of the following AEs: elevated aspartate amino-
transferase (AST), elevated alanine aminotransferase (ALT),
elevated lactate dehydrogenase, fatigue and hypertension.
Linear regression analysis was used to determine whether a
relationship existed between exposure and change in tumor size.
Results
Patient disposition
Between August 2007 and May 2009, 14 patients were
enrolled. Of these, only 11 treated patients had at least one
on-treatment scan. Recruitment was halted because no pa-
tient met the treatment response criterion (CR or PR)
required for continuation to stage 2. All patients had histo-
logically or cytologically confirmed SCCHN,with amean time
since the initial diagnosis of 1.4 years (range, 0–7 years).
All patients had distant metastatic disease, and 12 patients had
received prior antitumor therapy regimens and radiation ther-
apy (85.7 %). Two patients did not have any line of prior
therapy for recurrent and/or metastatic disease, four patients
had received only first-line therapy, six patients two lines of
prior therapy, and two patients three lines of prior therapy.
Chemotherapeutic drugs included platinating agents, taxanes,
5-FU, hydroxycarbamide, cetuximab and bevacizumab.
Table 1 presents the baseline demographics and Table 2 displays
the disposition of the 14 patients included in the study.
Efficacy
Although there were no confirmed PRs or CRs in this trial,
seven of 14 patients had SD and six of 14 patients experi-
enced some tumor shrinkage (range 5–21 %) (Fig. 1). The
median duration of SD was 4.1 months and the disease
stabilization rate was 50 % (Table 3). Two patients had
prolonged SD of 13 and 13.9 months’ duration, respectively.
Table 1 Baseline demographics
Category Measure
Age, years, median (range) 59.0 (48–82)





ECOG performance status, n (%)
0 9 (64.3)
1 5 (35.7)









Sites of metastases, n (%)
Bone 1 (7.1)




ECOG Eastern Cooperative Oncology Group
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The median duration of PFS was 3.65 months (Fig. 2).
The median OS was 5.59 months; five patients (35.7 %)
were alive at 6 months and two patients (14.3 %) at
12 months (Fig. 3).
Pharmacokinetics
For the exposure-response analysis, foretinib trough concen-
tration data were available for 11 patients; however, week
8 tumor size data were available for only nine patients. No
relationship was detected between average foretinib trough
concentrations after 4 days of dosing and percent change
from baseline to week 8 in the sum of the longest tumor
diameter (Supplemental Fig. 1).
Moreover, no relationship was detected between average
foretinib trough concentrations and the incidence of any AE.
Statistical tests were limited by the small sample size.
Safety and adverse events
All patients experienced at least one AE with 14 patients
evaluable for safety. Fatigue, constipation and hypertension
were the most common AEs, occurring in seven (50 %), five
(35.7 %), and five (35.7 %) patients, respectively (Table 4).
These were managed with additional medication (e.g. anti-
hypertensives) or dose delay and/or reduction. Of all AEs,
55 % were considered related to foretinib treatment. The most
frequent treatment-related grade 3 AEwas hypophosphatemia
(experienced by three patients). There were no grade 4
treatment-related AEs, but one fatal hemorrhage occurred
during cycle 7 and was considered possibly related to fore-
tinib. This patient had severe hemoptysis, and cardiopulmo-
nary resuscitation was unsuccessful.
A total of six other patients died during treatment or
follow-up. Four (28.6 %) of these deaths were due to pro-
gressive disease and two (14.3 %) due to other causes
(pneumonia/respiratory failure and reasons that were not
confirmed); none of these six deaths were attributed to the
study medication. Two of 14 patients (14 %) required dose
reductions to 160 mg due to AEs. No AEs occurred that
resulted in study drug discontinuation.
Discussion
Recurrent and/or metastatic SCCHN is a devastating disease
for which few effective treatment options are available. This
is the first report evaluating a MET inhibitor as a single
agent for SCCHN. While the response rate in this two-stage
phase II trial did not meet the criteria to allow progression to
stage 2, as there were no responders based on RECIST,
signs of moderate activity were evident: seven of 14 patients
(50 %) experienced SD and six of 14 patients (43 %)
showed tumor shrinkage of up to 21 %. Two patients (2/
14) (14 %) experienced SD over a period of 13 months or
more, exceeding the typical PFS of 3–5 months observed
with standard of care [7, 30].
Cetuximab is commonly used in the treatment of recur-
rent/metastatic disease, either in combination with chemo-
therapy or as a single agent [31, 32]. The addition of
cetuximab to chemotherapy as first-line treatment of
patients with recurrent or metastatic SCCHN increased the
response rate from 20 % to 36 % (P<0.001) and median
PFS from 3.3 to 5.6 months (P<0.001) [31]. As a single
agent, cetuximab has demonstrated only moderate activity
in a phase II study; the best response rate was 13 % (13/103
patients) and 33 % (34/103 patients) experienced SD [32].
The disease control rate was 46 % and the median TTP was
Table 2 Patient
disposition Reason for discontinuation Patients,
n (%)
Withdrawn by patient 2 (14.3)
Physician decision 1 (7.1)
Progressive disease 7 (50.0)
Lost to follow-up 1 (7.1)
Death 1 (7.1)
Other 2 (14.3)
Total discontinued 14 (100)
Fig. 1 Waterfall plot for best
percentage change from
baseline in target lesion tumor
measurement. Only 11 of the 14
treated patients had at least one
on-treatment scan to be includ-
ed. *Patient had a best percent-
age change from baseline in
tumor measurement of 0 %. At
that visit, the overall response
assessment was stable disease
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2.3 months [32]. Methotrexate as a single agent has been a
standard comparator for clinical studies and has shown
response rates of only 3.9 % (6/152 patients; PFS data not
reported) [33]. By comparison, foretinib in this (albeit much
smaller) study showed a PFS of 3.65 months and a disease
stabilization rate of 50 %.
There was no biomarker analysis performed in this study
to predict a response to treatment, and it is unclear from the
information obtained why the tumors did not respond as
predicted by the preclinical data. However, there are many
factors that could play a role: foretinib levels in the tumor
cells may not be high enough to sufficiently inhibit MET
with the intermittent 5/9 schedule, although pharmacody-
namic data and clinical data in papillary renal cell [24, 25]
and hepatocellular carcinoma [34] do support adequate target
inhibition [20]. Notably, inhibition of MET phosphorylation
and decreased proliferation in selected tumor biopsies were
observed in patients treated with submaximal doses of fore-
tinib [20]. A more likely explanation may be that the in vivo
situation is more complex than suggested by in vitro models.
One hypothesis may be that additional pathways to those
targeted by foretinib may contribute to MET resistance. In
future studies, serial biopsymay help elucidate mechanisms of
resistance.
We know from other cancer types that compensatory
RTK signaling can lead to tumor robustness and resistance
[22, 35], and co-targeting may increase efficacy. In non-
small cell lung cancer (NSCLC), MET inhibition increased
the efficacy of the EGFR inhibitor erlotinib in two large
randomized phase II trials [11, 36], despite limited single-
agent activity of the respective MET inhibitors in NSCLC
[37]. It is therefore reasonable to hypothesize that combined
MET/EGFR inhibition may be a promising approach for
SCCHN. This is supported by preclinical data showing
potent MET/EGFR synergy in SCCHN cell line models
[11, 21].
While this is a negative study that did not meet the
predefined statistical criteria to proceed to stage 2 of the
trial, it is also evident that there is modest activity in a high
proportion of SCCHN patients. If significant inhibition of
invasion and metastasis is achieved by foretinib treatment,
this may be clinically meaningful and efficacy assessment
by RECIST may not be optimal in assessing true clinical
benefit. In a recent study, time to development of new
metastatic lesions was evaluated with a different MET in-
hibitor (tivantinib) in combination with erlotinib in patients
with advanced NSCLC [38]. Time to new metastasis was
delayed with tivantinib plus erlotinib versus erlotinib alone
(7.3 vs 3.6 months, respectively; P<0.01). The effect was
more pronounced in patients with non-squamous histology
(median time to metastatic disease 11.0 vs 3.6 months,
respectively; P<0.01), whilst the objective response rates
Table 3 Tumor response and survival outcomes
Best overall response, n (%)
Complete response 0
Partial response 0
Stable disease 7 (50.0)
Disease progression 3 (21.4)
Unable to evaluate 1 (7.1)
Objective response rate, % (95 % CI) 0 (0–23.2)
Disease stabilization ratea, % (95 % CI) 7 (50) (23.0–77.0)
Duration of stable diseaseb, months (95 % CI) 4.11 (3.65–13.86)
Progression-free survival, months, median
(95 % CI)
3.65 (3.4–5.3)
Overall survival, months, median (95 % CI) 5.59 (3.71–NA)
a Proportion of patients achieving a best overall response of complete
response, partial response, or stable disease
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were only 10 % (7/74 patients) vs 7 % (5/72 patients),
respectively (PRs only) [38]. These data further support
the evaluation of time to metastatic disease with MET
inhibitors in follow-up studies. Furthermore, the anti-
angiogenic effect of foretinib may result in a metabolic
response against the tumor rather than tumor shrinkage.
Future studies should take this into consideration as well
as incorporating biomarker analyses to help understand and
predict a response to treatment.
Foretinib was well tolerated, with the most common AEs
(fatigue, constipation and hypertension) being readily man-
ageable, and the most common foretinib-related laboratory
abnormalities (elevated ALT and AST) being asymptomatic.
Thus, foretinib may be a good candidate for combination
therapy. At this point, no validated biomarkers are available
and the small sample size precludes further analysis. There
are several potential biomarker candidates, including MET
immunohistochemistry [39] and MET copy number [38].
Foretinib is not a MET-specific inhibitor. Like many
MET tyrosine kinase inhibitors, it also inhibits the MET-
like kinase RON, which is functionally similar to MET [22].
In contrast to other more specific MET inhibitors, foretinib
also inhibits VEGFR2 and TIE-2 at clinically achievable
concentrations. Inhibition of these multiple targets may have
contributed to the modest activity seen; however, further
exploration is required [40]. The activity of foretinib against
targets in addition to MET may provide a good basis for
achieving better outcomes with combination therapy in the
future.
No AEs related to MET inhibition were reported; how-
ever, AEs related to VEGF inhibition were observed.
Observations included night blindness in some patients re-
ceiving foretinib [24], other ocular toxicities with crizotinib
[41], a MET/ALK inhibitor, and hematologic toxicities with
tivantinib [42], an inhibitor of MET. The fact that the three
MET inhibitors do not result in similar toxicities suggests
that these effects may be potentially unrelated to MET
inhibition.
In conclusion, this is the first report of a MET inhibitor
used for SCCHN. There is evidence of modest activity,
despite the lack of objective responses to treatment.




Table 4 Most common (>2 patients) adverse events
Eventa Patients,
n (%)
Grade 3, 4, or
5, n (%)
Fatigue 7 (50.0) 2 (14.3)
Constipation 5 (35.7) –
Hypertension 5 (35.7) 1 (7.1)
Alanine aminotransferase increase 4 (28.6) –
Anorexia 4 (28.6) –
Aspartate aminotransferase increase 4 (28.6) –
Dysphagia 4 (28.6) 1 (7.1)
Dyspnea 4 (28.6) 1 (7.1)
Headache 4 (28.6) –
Mucosal inflammation 4 (28.6) –
Weight decrease 4 (28.6) –
Dehydration 3 (21.4) 2 (14.4)
Depression 3 (21.4) –
Dizziness 3 (21.4) –
Dry skin 3 (21.4) –
Hypophosphatemia 3 (21.4) 3 (21.4)
Insomnia 3 (21.4) –
Musculoskeletal pain 3 (21.4) –
Nausea 3 (21.4) –
Rash 3 (21.4) –
a Treatment-emergent AE was defined as any AE with an onset date on
or after the date of first dose of study drug, or any ongoing event that
worsened in intensity after the date of first dose, but before the date of
last dose plus 30 days
AEs adverse events
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Furthermore, preclinical data, as well as clinical observa-
tions, in NSCLC suggest that combination approaches with
EGFR inhibition may be promising and should be explored
further.
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